2021-05-10 Legal Press releases

Notice of annual general meeting in Intervacc AB (publ)

The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Wednesday 9 June 2021.

Due to the continued spread of the ... Read more

2021-04-12 Legal Press releases

Intervacc AB and Dechra Pharmaceuticals PLC enter into an Agreement to Commercialize Strangvac in Europe

Stockholm, April 12, 2021 - Intervacc AB (“Intervacc”) announced today that they have entered into an exclusive distribution agreement with Dechra Pharmaceuticals PLC, (“Dechra”) to commercialize Intervacc’s leading ... Read more

2021-03-31 Legal Press releases

Intervacc publishes the 2020 Annual Report

Stockholm, March 31, 2021 - Intervacc AB (publ) announces that the company's 2020 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is ... Read more

2021-03-09 Legal Press releases

DNA investigation highlights the ‘unbridled globetrotting’ of the Strangles pathogen in horses

Stockholm, March 9, 2021 - In the largest ever study of its kind into an equine pathogen, which was published today in the journal 'Microbial Genomics', scientists in 18 countries used the latest DNA sequencing techniques to ... Read more

2021-02-18 Legal Press releases

Year-end report January – December 2020

The period in summary

January 1 – December 31, 2020

• Our marketing authorization application for Strangvac^® was submitted to the European Medicines Agency, EMA, at the end of February 2020. After having ... Read more

2021-01-12 Legal Press releases

Intervacc Announces Submission of Responses to EMA Day 120 Questions

Stockholm, January 12, 2021 - Intervacc AB (publ) announces that the responses to the Day 120 questions regarding the Company’s Marketing Authorization Application (MAA) for Strangvac^® has been submitted today ... Read more